Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide. The only drug currently approved for clinical use in the treatment of advanced HCC is sorafenib. However, many patients with HCC show reduced sensitivity to sorafenib during treatment. | Modulation of SIRT3 expression through CDK4 6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells